Advertisement
Canada markets closed

  • S&P/TSX

    22,308.93
    +361.53 (+1.65%)
     

  • S&P 500

    5,222.68
    +94.89 (+1.85%)
     

  • DOW

    39,512.84
    +837.14 (+2.16%)
     

  • CAD/USD

    0.7312
    -0.0005 (-0.07%)
     

  • CRUDE OIL

    78.06
    -0.20 (-0.26%)
     

  • Bitcoin CAD

    84,022.78
    +870.79 (+1.05%)
     

  • CMC Crypto 200

    1,269.77
    -42.86 (-3.27%)
     

  • GOLD FUTURES

    2,367.00
    -8.00 (-0.34%)
     

  • RUSSELL 2000

    2,059.78
    +24.06 (+1.18%)
     

  • 10-Yr Bond

    4.5040
    +0.0040 (+0.09%)
     

  • NASDAQ futures

    18,251.25
    -3.75 (-0.02%)
     

  • VOLATILITY

    12.55
    -0.94 (-6.97%)
     

  • FTSE

    8,433.76
    +261.61 (+3.20%)
     

  • NIKKEI 225

    38,229.11
    -44.99 (-0.12%)
     

  • CAD/EUR

    0.6785
    -0.0004 (-0.06%)
     

Valeant CEO 'disappointed' in Allergan poison pill: CNBC

Reuters
A sample of Botox is seen at the Long Island Plastic Surgical Group at the Americana Manhasset luxury shopping destination in Manhasset, New York September 30, 2010. REUTERS/Shannon Stapleton (Reuters)

(Reuters) - The chief executive officer of Valeant Pharmaceuticals, which made a $47 billion unsolicited offer for competitor Allergan Inc on Tuesday, said during an interview on CNBC that he was "disappointed" with Allergan's so-called poison pill. Allergan on Tuesday night said its board of directors had adopted a one-year stockholder rights plan to give it more time to consider takeover proposals. The Valeant offer was made with Pershing Square Capital Management hedge fund, which built up a stake in the company. "We are disappointed but on the other hand, I think this deal will get done," Valeant CEO Michael Pearson said on Wednesday. (Reporting by Caroline Humer; Editing by Chizu Nomiyama)